Compare BioNTech SE - ADR (BNTX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Upwork Inc — how do they compare? BioNTech SE - ADR trades at $90.28 (market cap $22.86B), while Upwork Inc trades at $9.19 (market cap $1.12B). The key difference: BioNTech SE - ADR is far larger — about 20.4× Upwork Inc's market cap. Which is the better fit depends on your goals.
| BNTX | UPWK | |
|---|---|---|
Market Cap | $22.86B | $1.12B |
Sector | Health | Industrials |
52-Week High | $119.34 | $22.11 |
52-Week Low | $83.89 | $7.84 |
Enterprise Value | $6.53B | $915.11M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
UPWK trades at $9.12, up 3.4% today, with a bullish technical signal from moving averages. The company reported $787.78M revenue and $115.43M net income for 2025, with strong profitability margins. Recent news highlights AI integration initiatives and board refreshment, but multiple law firms are investigating potential securities law violations following earnings misses and a guidance cut.
The outlook is mixed: analyst consensus is a Buy with a $10.67 price target, but earnings misses and legal scrutiny pose risks. Revenue growth has slowed, and net cash flow turned negative in 2025. Upside depends on successful AI adoption and execution, while downside risks include ongoing investigations and competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
